HUE053904T2 - Hosszan tartó hatású injektálható paliperidon-észterekkel kapcsolatos adagolási rendek - Google Patents
Hosszan tartó hatású injektálható paliperidon-észterekkel kapcsolatos adagolási rendekInfo
- Publication number
- HUE053904T2 HUE053904T2 HUE08863534A HUE08863534A HUE053904T2 HU E053904 T2 HUE053904 T2 HU E053904T2 HU E08863534 A HUE08863534 A HU E08863534A HU E08863534 A HUE08863534 A HU E08863534A HU E053904 T2 HUE053904 T2 HU E053904T2
- Authority
- HU
- Hungary
- Prior art keywords
- dosing regimen
- long acting
- acting injectable
- regimen associated
- injectable paliperidone
- Prior art date
Links
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical class FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L21/00—Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
-
- H—ELECTRICITY
- H01—ELECTRIC ELEMENTS
- H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
- H01L31/00—Semiconductor devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation and specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof; Details thereof
- H01L31/08—Semiconductor devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation and specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof; Details thereof in which radiation controls flow of current through the device, e.g. photoresistors
- H01L31/10—Semiconductor devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation and specially adapted either for the conversion of the energy of such radiation into electrical energy or for the control of electrical energy by such radiation; Processes or apparatus specially adapted for the manufacture or treatment thereof or of parts thereof; Details thereof in which radiation controls flow of current through the device, e.g. photoresistors characterised by potential barriers, e.g. phototransistors
- H01L31/101—Devices sensitive to infrared, visible or ultraviolet radiation
- H01L31/102—Devices sensitive to infrared, visible or ultraviolet radiation characterised by only one potential barrier
- H01L31/109—Devices sensitive to infrared, visible or ultraviolet radiation characterised by only one potential barrier the potential barrier being of the PN heterojunction type
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Computer Hardware Design (AREA)
- Microelectronics & Electronic Packaging (AREA)
- Power Engineering (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Dermatology (AREA)
- Manufacturing & Machinery (AREA)
- Electromagnetism (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Dispersion Chemistry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1491807P | 2007-12-19 | 2007-12-19 | |
US12027608P | 2008-12-05 | 2008-12-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE053904T2 true HUE053904T2 (hu) | 2021-07-28 |
Family
ID=40428256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE08863534A HUE053904T2 (hu) | 2007-12-19 | 2008-12-17 | Hosszan tartó hatású injektálható paliperidon-észterekkel kapcsolatos adagolási rendek |
Country Status (26)
Country | Link |
---|---|
US (3) | US9439906B2 (hu) |
EP (2) | EP2234617B1 (hu) |
JP (1) | JP5825786B2 (hu) |
KR (3) | KR102318070B1 (hu) |
CN (2) | CN105560176A (hu) |
AU (2) | AU2008340101B2 (hu) |
BR (1) | BRPI0821408A2 (hu) |
CO (1) | CO6300949A2 (hu) |
CY (1) | CY1124103T1 (hu) |
DK (1) | DK2234617T3 (hu) |
EA (1) | EA020697B1 (hu) |
EC (1) | ECSP10010289A (hu) |
ES (1) | ES2868353T3 (hu) |
GT (1) | GT201000182A (hu) |
HK (1) | HK1223850A1 (hu) |
HR (1) | HRP20210669T1 (hu) |
HU (1) | HUE053904T2 (hu) |
IL (2) | IL206448A (hu) |
LT (1) | LT2234617T (hu) |
NI (1) | NI201000105A (hu) |
NZ (1) | NZ586221A (hu) |
PL (1) | PL2234617T3 (hu) |
PT (1) | PT2234617T (hu) |
RS (1) | RS61765B1 (hu) |
SI (1) | SI2234617T1 (hu) |
WO (1) | WO2009080651A1 (hu) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA72189C2 (uk) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
SI2234617T1 (sl) | 2007-12-19 | 2021-07-30 | Janssen Pharmaceutica Nv | Režim odmerjanja v zvezi z dolgodelujočimi paliperidonijevimi estri za injiciranje |
US8758780B2 (en) * | 2009-10-06 | 2014-06-24 | Ascendis Pharma As | Subcutaneous paliperidone composition |
WO2011042450A1 (en) | 2009-10-06 | 2011-04-14 | Ascendis Pharma As | Carrier linked paliperidone prodrugs |
MX2012005083A (es) * | 2009-10-30 | 2012-09-28 | Janssen Pharmaceutica Nv | Regimen de dosificacion asociado con esteres de paliperidona inyetables de accion prolongada. |
EP2547206B1 (en) | 2010-03-15 | 2016-05-11 | Inventia Healthcare Private Limited | Stabilized prolonged release pharmaceutical composition comprising atypical antipsychotic |
US9522980B2 (en) | 2010-05-06 | 2016-12-20 | Johnson & Johnson Vision Care, Inc. | Non-reactive, hydrophilic polymers having terminal siloxanes and methods for making and using the same |
TWI577377B (zh) * | 2010-09-16 | 2017-04-11 | Viiv醫療保健公司 | 醫藥組合物 |
DK3156056T3 (da) * | 2011-03-18 | 2024-02-26 | Alkermes Pharma Ireland Ltd | Farmaceutiske sammensætninger der består af sorbitanestere |
US9170349B2 (en) | 2011-05-04 | 2015-10-27 | Johnson & Johnson Vision Care, Inc. | Medical devices having homogeneous charge density and methods for making same |
ES2878112T3 (es) | 2011-05-31 | 2021-11-18 | Farm Rovi Lab Sa | Formulación de implante de risperidona y/o paliperidona |
SI2529757T1 (sl) | 2011-05-31 | 2014-05-30 | Laboratorios Farmaceuticos Rovi, S.A. | Formulacija paliperidon implantata |
CN102274164B (zh) * | 2011-08-22 | 2014-07-02 | 长春健欣生物医药科技开发有限公司 | 帕潘立酮及帕潘立酮衍生物的注射用缓释凝胶剂 |
CN103301461B (zh) * | 2012-03-08 | 2018-09-07 | 江苏豪森药业集团有限公司 | 一种长效注射制剂及其制备方法和用途 |
ES2950418T3 (es) | 2012-03-19 | 2023-10-09 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que comprenden alcohol bencílico |
CA2867121C (en) | 2012-03-19 | 2021-05-25 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising fatty acid esters |
JP6219918B2 (ja) | 2012-03-19 | 2017-10-25 | アルカームス ファーマ アイルランド リミテッド | グリセロールエステルを含む医薬組成物 |
US10073192B2 (en) | 2012-05-25 | 2018-09-11 | Johnson & Johnson Vision Care, Inc. | Polymers and nanogel materials and methods for making and using the same |
US9244196B2 (en) | 2012-05-25 | 2016-01-26 | Johnson & Johnson Vision Care, Inc. | Polymers and nanogel materials and methods for making and using the same |
NZ730571A (en) | 2012-09-19 | 2018-12-21 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions having improved storage stability |
MX2016012041A (es) | 2014-03-20 | 2017-01-19 | Alkermes Pharma Ireland Ltd | Formulaciones de aripiprazol que tienen mayores velocidades de inyeccion. |
ES2862098T3 (es) | 2014-08-25 | 2021-10-07 | Alkermes Pharma Ireland Ltd | Proceso de cristalización de derivados de aripiprazol en formulaciones de liberación prolongada para el tratamiento de la esquizofrenia |
US9844551B2 (en) | 2015-01-14 | 2017-12-19 | Children's Hospital Medical Center | Compositions and methods for treatment of fragile X syndrome |
BR112017017608A2 (pt) * | 2015-02-17 | 2018-05-08 | Vanda Pharmaceuticals Inc | métodos para tratamento de esquizofrenia ou um sintoma de esquizofrenia, para prevenir uma recaída esquizofrênica e para manter o efeito de iloperidona para esquizofrenia. |
WO2016157061A1 (en) | 2015-03-31 | 2016-10-06 | Wockhardt Limited | Aseptic wet milling process for paliperidone palmitate |
WO2016164218A1 (en) | 2015-04-07 | 2016-10-13 | Janssen Pharmaceuticals, Inc. | Dosing regimen for missed doses for long-acting injectable paliperidone esters |
WO2018098115A1 (en) * | 2016-11-23 | 2018-05-31 | Children's Hospital Medical Center | Paliperidone for treatment of drug refractory irritability and autism spectrum disorder |
JP7337080B2 (ja) * | 2017-10-27 | 2023-09-01 | 嘉奥制薬(石家庄)有限公司 | パリペリドンパルミチン酸エステル徐放性懸濁注射液の投薬レジメン |
CA3092335A1 (en) | 2018-03-05 | 2019-09-12 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
CN110279659A (zh) * | 2019-07-08 | 2019-09-27 | 华裕(无锡)制药有限公司 | 棕榈酸帕利哌酮制剂及其制备方法 |
GR1009869B (el) * | 2019-07-12 | 2020-11-12 | Φαρματεν Α.Β.Ε.Ε. | Ενεσιμο παρατεταμενης αποδεσμευσης φαρμακευτικο σκευασμα που περιλαμβανει παλμιτικη παλιπεριδονη και μεθοδος παρασκευης αυτου |
WO2022006336A1 (en) * | 2020-07-01 | 2022-01-06 | Jubilant Pharma Holdings Inc. | Long-acting injection dosage form of beta 3 adrenoreceptor agonists |
RS65178B1 (sr) | 2020-11-30 | 2024-03-29 | Janssen Pharmaceutica Nv | Režimi doziranja povezani sa injekcionim formulacijama paliperidona sa produženim oslobađanjem |
KR20230116836A (ko) | 2020-11-30 | 2023-08-04 | 얀센 파마슈티카 엔.브이. | 서방형 팔리페리돈 주사용 제형과 관련된 투약 요법 |
US11666697B2 (en) | 2020-11-30 | 2023-06-06 | Janssen Pharmaceutica Nv | Methods for ensuring resuspension of paliperidone palmitate formulations |
WO2022111858A1 (en) | 2020-11-30 | 2022-06-02 | Janssen Pharmaceutica Nv | Dosing regimens associated with extended release paliperidone injectable formulations |
RU2756614C1 (ru) * | 2021-04-07 | 2021-10-04 | Федеральное государственное бюджетное научное учреждение «Томский национальный исследовательский медицинский центр Российской академии наук» (Томский НИМЦ) | Способ поддержки принятия врачебных решений выбора антипсихотической терапии у больных шизофренией с целью профилактики акатизии |
MX2024002215A (es) | 2021-08-20 | 2024-05-10 | Janssen Pharmaceutica Nv | Regímenes de dosificación asociados con formulaciones inyectables de paliperidona de liberación prolongada. |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1491807A (en) | 1922-06-20 | 1924-04-29 | John P Mclinn | Traveling bag |
US1491809A (en) | 1923-02-17 | 1924-04-29 | Us Fireworks Mfg Company Inc | Toy |
US4804663A (en) * | 1985-03-27 | 1989-02-14 | Janssen Pharmaceutica N.V. | 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles |
US5254556A (en) | 1988-11-07 | 1993-10-19 | Janssen Pharmaceutica N.V. | 3-piperidinyl-1,2-benzisoxazoles |
US5158952A (en) * | 1988-11-07 | 1992-10-27 | Janssen Pharmaceutica N.V. | 3-[2-[4-(6-fluoro-1,2-benzisoxozol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9 tetrahydro-9-hydroxy-2-methyl-4H-pyrido [1,2-a]pyrimidin-4-one, compositions and method of use |
TW376319B (en) * | 1993-04-28 | 1999-12-11 | Janssen Pharmaceutica Nv | Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine |
US5453425A (en) * | 1994-07-11 | 1995-09-26 | Janssen Pharmaceutica N.V. | Risperidone oral formulation |
TW487572B (en) | 1996-05-20 | 2002-05-21 | Janssen Pharmaceutica Nv | Aqueous suspensions of 9-hydroxyrisperidone fatty acid esters |
UA72189C2 (uk) | 1997-11-17 | 2005-02-15 | Янссен Фармацевтика Н.В. | Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот |
AU5489299A (en) * | 1998-08-18 | 2000-03-14 | Sepracor, Inc. | Use of hydroxyrisperidone for the manufacture of a medicament for the treatment and prevention of psychoses, emesis and symptoms of withdrawal from alcohol and nicotine |
KR100338776B1 (ko) | 2000-07-11 | 2002-05-31 | 윤종용 | 멀티 로우 어드레스 테스트 가능한 반도체 메모리 장치 및그 테스트 방법 |
DE60316454T2 (de) | 2002-07-29 | 2008-06-26 | Alza Corp., Mountain View | Verfahren und dosierformen für die kontrollierte abgabe von paliperidon |
US7387623B2 (en) | 2002-08-21 | 2008-06-17 | Pfizer Inc. | Injectable pharmaceutical suspension in a two-chamber vial |
US20060079846A1 (en) | 2004-10-08 | 2006-04-13 | Alton Williams | Hypodermic syringes with multiple needles and methods of calming psychiatric patients using such |
CN101163702B (zh) * | 2005-04-25 | 2011-09-07 | 詹森药业有限公司 | 制备无菌的3-[2-[4-(6-氟-1,2-苯并异唑-3-基)-1-哌啶基]乙基]-6,7,8,9-四氢-9-羟基-2-甲基-4H-吡啶并[1,2-a]嘧啶-4-酮棕榈酸酯的方法 |
US20070197591A1 (en) * | 2005-12-12 | 2007-08-23 | Sandra Boom | Use of paliperidone for the treatment of a mental disorder in a psychiatric patient with reduced hepatic function |
US20070232624A1 (en) * | 2006-04-03 | 2007-10-04 | Palumbo Joseph M | Use of paliperidone for the treatment of sleep disturbances and/or excessive daytime sleepiness in psychiatric patients |
EP1940834A2 (en) | 2006-08-14 | 2008-07-09 | Teva Pharmaceutical Industries Ltd. | Amorphous and crystalline forms of 9-hydroxy-risperidone (paliperidone) |
PT2079446E (pt) | 2007-08-21 | 2011-12-23 | Teva Pharma | Formulação de libertação sustida de paliperidona |
WO2009047499A2 (en) | 2007-10-09 | 2009-04-16 | Cipla Limited | Processes for the preparation of paliperidone and pharmaceutically acceptable salts thereof and intermediates for use in the processes |
SI2234617T1 (sl) | 2007-12-19 | 2021-07-30 | Janssen Pharmaceutica Nv | Režim odmerjanja v zvezi z dolgodelujočimi paliperidonijevimi estri za injiciranje |
MX2012005083A (es) * | 2009-10-30 | 2012-09-28 | Janssen Pharmaceutica Nv | Regimen de dosificacion asociado con esteres de paliperidona inyetables de accion prolongada. |
US11114549B2 (en) | 2017-11-29 | 2021-09-07 | Taiwan Semiconductor Manufacturing Co., Ltd. | Semiconductor structure cutting process and structures formed thereby |
US11450758B2 (en) | 2020-06-12 | 2022-09-20 | Taiwan Semiconductor Manufacturing Co., Ltd. | Gate structure of semiconductor device and method of forming same |
-
2008
- 2008-12-17 SI SI200832163T patent/SI2234617T1/sl unknown
- 2008-12-17 KR KR1020197012533A patent/KR102318070B1/ko active IP Right Grant
- 2008-12-17 AU AU2008340101A patent/AU2008340101B2/en active Active
- 2008-12-17 RS RS20210495A patent/RS61765B1/sr unknown
- 2008-12-17 CN CN201610011987.6A patent/CN105560176A/zh active Pending
- 2008-12-17 ES ES08863534T patent/ES2868353T3/es active Active
- 2008-12-17 HU HUE08863534A patent/HUE053904T2/hu unknown
- 2008-12-17 PL PL08863534T patent/PL2234617T3/pl unknown
- 2008-12-17 CN CN2008801261088A patent/CN101932327A/zh active Pending
- 2008-12-17 LT LTEP08863534.7T patent/LT2234617T/lt unknown
- 2008-12-17 EA EA201070757A patent/EA020697B1/ru not_active IP Right Cessation
- 2008-12-17 KR KR1020177003860A patent/KR102163196B1/ko active IP Right Grant
- 2008-12-17 WO PCT/EP2008/067738 patent/WO2009080651A1/en active Application Filing
- 2008-12-17 US US12/337,144 patent/US9439906B2/en active Active
- 2008-12-17 EP EP08863534.7A patent/EP2234617B1/en active Active
- 2008-12-17 DK DK08863534.7T patent/DK2234617T3/da active
- 2008-12-17 KR KR1020107015670A patent/KR20100099292A/ko active Search and Examination
- 2008-12-17 NZ NZ586221A patent/NZ586221A/xx unknown
- 2008-12-17 JP JP2010538703A patent/JP5825786B2/ja active Active
- 2008-12-17 EP EP21164550.2A patent/EP3909585A1/en active Pending
- 2008-12-17 PT PT88635347T patent/PT2234617T/pt unknown
- 2008-12-17 BR BRPI0821408-5A patent/BRPI0821408A2/pt not_active Application Discontinuation
-
2010
- 2010-06-17 IL IL206448A patent/IL206448A/en unknown
- 2010-06-18 EC EC2010010289A patent/ECSP10010289A/es unknown
- 2010-06-18 GT GT201000182A patent/GT201000182A/es unknown
- 2010-06-18 NI NI201000105A patent/NI201000105A/es unknown
- 2010-06-23 CO CO10075713A patent/CO6300949A2/es not_active Application Discontinuation
-
2015
- 2015-02-18 AU AU2015200801A patent/AU2015200801B2/en active Active
-
2016
- 2016-08-25 US US15/247,149 patent/US20170128451A1/en not_active Abandoned
- 2016-10-26 HK HK16112292.2A patent/HK1223850A1/zh unknown
-
2017
- 2017-07-13 IL IL253468A patent/IL253468A0/en unknown
-
2018
- 2018-01-25 US US15/880,160 patent/US20180147210A1/en not_active Abandoned
-
2021
- 2021-04-27 HR HRP20210669TT patent/HRP20210669T1/hr unknown
- 2021-05-12 CY CY20211100404T patent/CY1124103T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL253468A0 (en) | Dosing regimen associated with long-acting injectable paliperidone esters | |
ZA201100494B (en) | Auto-injector with filling means | |
ZA201301436B (en) | Dispenser with level sensor | |
SI3199172T1 (sl) | Odmerni režim za multiplo sklerozo | |
GB0823693D0 (en) | Autoinjector | |
IL209370A0 (en) | Dosing regimen | |
EP2298392A4 (en) | INJECTION DEVICE | |
BR112012010195A2 (pt) | regime de dosagem associado a ésteres de paliperidona injetável de longa ação | |
HK1134806A1 (en) | Hopper structure | |
EP2197448A4 (en) | dosing schedule | |
EP2323856A4 (en) | GAS BARRIER WITH AN ALIPHATIC RESIN | |
GB0901924D0 (en) | Imprived autoinjector | |
EP2288900A4 (en) | FRAME WITH FLUIDS | |
IL212811A0 (en) | Container with additional external panel | |
IL222277A0 (en) | Pharmaceutical compositions highly dosed with biotin | |
IL206739A0 (en) | Injectable pharmaceutical composition | |
GB0704573D0 (en) | Multi-use retaining means | |
GB0813299D0 (en) | Injectable medications | |
GB0714114D0 (en) | Injectable medications | |
GB0805331D0 (en) | Fuel container | |
IL199679A0 (en) | Injectable pharmaceutical composition | |
GB0807695D0 (en) | Container with liner | |
PL391348A1 (pl) | Zbiornik o konstrukcji panelowej | |
GB0819199D0 (en) | Furniture with detachable arpro | |
PL384667A1 (pl) | Dozownik |